文献速递临床试验与 GCP流行病学与生物统计

盐替代品与食盐供应限制对养老机构老年人降压效果的整群随机试验

Salt substitution and salt-supply restriction for lowering blood pressure in elderly care facilities: a cluster-randomized trial.
PubMed 文献 · Nat Med · 2023-04-13

在中国48家养老机构(1612名55岁及以上居民)开展2×2析因整群随机试验,比较盐替代品(62.5% NaCl和25% KCl)与普通盐、以及渐进限制与常规供应食盐或盐替代品持续2年。盐替代品使收缩压降低7.1 mmHg(95%CI -10.5至-3.8),达到主要结局,并减少心血管事件(HR 0.60,95%CI 0.38-0.96),但增加生化性高钾血症;限制食盐供应对任何研究结局均无影响。

要点

  • 盐替代品较普通盐使收缩压降低7.1 mmHg(95%CI -10.5至-3.8),达到主要结局。
  • 盐替代品使心血管事件减少(HR 0.60,95%CI 0.38-0.96),但对总死亡率无影响(HR 0.84,95%CI 0.63-1.13)。
  • 限制食盐或盐替代品供应对收缩压及任何研究结局均无影响。

核心结论

  • 在中国养老机构居民中,使用盐替代品而非限制食盐供应可能实现降压并带来健康获益。

研究设计与样本

  • 在中国48家养老机构开展2×2析因整群随机临床试验,纳入1612名55岁及以上居民(男1230人、女382人)。
  • 干预为盐替代品(62.5% NaCl和25% KCl)对比普通盐,以及渐进限制对比常规供应食盐或盐替代品,持续2年。

主要发现

  • 盐替代品对比普通盐使收缩压降低7.1 mmHg(95%CI -10.5至-3.8),达到主要结局。
  • 盐替代品对比普通盐使舒张压降低1.9 mmHg(95%CI -3.6至-0.2)。
  • 盐替代品对比普通盐使心血管事件减少(HR 0.60,95%CI 0.38-0.96),对总死亡率无影响(HR 0.84,95%CI 0.63-1.13)。
  • 盐替代品升高平均血清钾并导致更频繁的生化性高钾血症,但与不良临床结局无关。
  • 限制供应对比常规供应食盐或盐替代品对收缩压无影响,对任何研究结局均无影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is a paucity of high-quality evidence on the effectiveness and safety of salt reduction strategies, particularly for older people, who have the most to benefit but are at higher risk of adverse effects. Here, we conducted a clinical trial in which 48 residential elderly care facilities in China (1,612 participants including 1,230 men and 382 women, 55 years or older) were cluster-randomized using a 2 × 2 factorial design to provision of salt substitute (62.5% NaCl and 25% KCl) versus usual salt and to a progressively restricted versus usual supply of salt or salt substitute for 2 years. Salt substitute compared with usual salt lowered systolic blood pressure (-7.1 mmHg, 95% confidence interval (CI) -10.5 to -3.8), meeting the primary outcome of the trial, whereas restricted supply compared with usual supply of salt or salt substitute had no effect on systolic blood pressure. Salt substitute also lowered diastolic blood pressure (-1.9 mmHg, 95% CI -3.6 to -0.2) and resulted in fewer cardiovascular events (hazard ratio (HR) 0.60, 95% CI 0.38-0.96), but had no effect on total mortality (HR 0.84, 95% CI 0.63-1.13). From a safety standpoint, salt substitute increased mean serum potassium and led to more frequent biochemical hyperkalemia, but was not associated with adverse clinical outcomes. In contrast, salt restriction had no effect on any study outcome. The results of this trial indicate that use of salt substitute, but not efforts to restrict salt supply, may achieve blood pressure lowering and deliver health benefits to residents of elderly care facilities in China. Clinicaltrials.gov registration: NCT03290716.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Yuan Y, Jin A, Neal B, et al. Salt substitution and salt-supply restriction for lowering blood pressure in elderly care facilities: a cluster-randomized trial. Nat Med. 2023. PMID: 37055566. doi:10.1038/s41591-023-02286-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。